VIVES Partners

Et si?vous appreniez que vous risquez de perdre jusqu’à 40 % de votre production ???? ?? La nouvelle ne serait franchement pas bonne… C’est pourtant une réalité pour nos agriculteurs : chaque année, entre 20 et 40 % des récoltes mondiales sont détruites par des champignons parasites. ? La spin-off BiocSol a décidé de s’attaquer de front à cette problématique en créant des solutions innovantes et durables pour protéger les cultures tout en préservant l’environnement et la biodiversité. ? Après dix ans de recherche à l’UCLouvain - Université catholique de Louvain et de premiers essais terrain concluants, l’entreprise se lance sur le marché des produits phytosanitaires avec un biopesticide de nouvelle génération. En exploitant des substances spécifiques d’origine microbienne, les biosolutions créées par BiocSol présentent des performances renforcées en termes d’efficacité et de stabilité notamment contre le mildiou des pommes de terre et des raisins. ? Moins d’un an après sa création, BiocSol lève 5,2 millions d’euros lors de son premier tour de financement. Cette levée de fonds, soutenue par Agri Investment Fund et VIVES Partners, confirme le fort potentiel du produit sur le marché. ? IMBC Spinnova, aux c?tés d’invest.bw, participe à hauteur de 500.000 € chacun pour soutenir cette initiative prometteuse. ? Nous sommes fiers de soutenir ce projet stratégique pour l’agriculture de demain.??? ?? ? Bravo à Simon Caulier pour le chemin parcouru?! ? #Environnement?#developpementdurable #Biopesticides #AgricultureDeDemain #InnovationAgricole

We are pleased to support Generare in its seed funding round! ?? ? ?? Generare is taking bacteria found in soil and breaking down their genetic code to uncover untapped bioactive molecules, called Natural Products (NPs), at unprecedented speed. ? ?? NPs were once the gold-standard for drug-discovery; penicillin being a prime example. They have led to 500+ anticancer, antibiotics and immunosuppressive drugs, yet their discovery in recent years has plateaued even though molecules from microbes are 100x more likely to gain approval than those from plants or chemistry. ? ?? Generare is reopening this critical avenue of discovery and doing so at scale. Using its patent-pending techniques it has already identified 100+ previously unknown molecules. ? ?? We are proud to support such an innovative company utilizing natural products, which we truly believe is the future of the agricultural, biotech and pharma sectors. ? ?? Congratulations to Guillaume Vandenesch, Dr Vincent Libis and the Generare team, we can’t wait to see what you do next! Teampact.ventures Galion.exe SynBioVen Saras Capital Better Angle ? #seedfunding #biotech #agritech #naturalproducts #funding #syntheticbio #innovation

?? We are delighted to announce our VIVES portfolio company BiocSol has secured €5.2M in seed funding! ? ?? Built on a decade of research at Université catholique de Louvain, BiocSol is redefining sustainable agriculture with its next-generation microbial-based solutions. By using secondary metabolites, these eco-friendly innovations deliver enhanced stability and effectiveness, ensuring reliable protection for key crops like potatoes, grapes, and vegetables—paving the way for a more sustainable future in farming.?? ? VIVES co-led the round with Agri Investment Fund bringing in new investors, invest.bw and IMBC SPINNOVA SA?onboard ?? ? Warm congrats to Denis Payen and Simon Caulier for this incredible milestone ? Read the full press release ?? https://lnkd.in/dvHqmKMU ? #agtech #midldew #lateblight #biofungicide #cropcare #sustainability #innovation #agriculture #farming #impact #resilience #UCLouvain

?? Congratulations to NOVADIP Biosciences S.A., a VIVES portfolio company, on receiving FDA IND approval to advance to a Phase 2b/3 clinical trial of NVDX3 for cervical spine fusion! ? ?? This milestone represents a pivotal moment for the orthopedic sector and a major step forward for patients suffering from fracture nonunions, which account for 5–10% of all bone traumas—or approximately 2 million impaired fractures annually. The global economic impact of fracture nonunion is staggering, with costs estimated at $20–30 billion per year, driven by medical expenses, prolonged treatments, and productivity losses. ? ?? Backed by robust preclinical and clinical data, NVDX3 has the potential to replace current graft products, offering enhanced safety and superior bone fusion for patients with complex comorbidities, ultimately improving recovery outcomes and surgical success. ? As investors in Novadip, we are proud to support this transformative journey, delivering safe and easy-to-use solutions to the patients who need them most. ? ? This is the perfect timing for Novadip, as the company prepares for its $50M fundraising round!?? #funding #nonunion #SpineSurgery #FDAApproval #NVDX3 #HealthTech #ClinicalTrials

?? Congratulations to NOVADIP Biosciences S.A., a VIVES portfolio company, on receiving FDA IND approval to advance to a Phase 2b/3 clinical trial of NVDX3 for cervical spine fusion! ? ?? This milestone represents a pivotal moment for the orthopedic sector and a major step forward for patients suffering from fracture nonunions, which account for 5–10% of all bone traumas—or approximately 2 million impaired fractures annually. The global economic impact of fracture nonunion is staggering, with costs estimated at $20–30 billion per year, driven by medical expenses, prolonged treatments, and productivity losses. ? ?? Backed by robust preclinical and clinical data, NVDX3 has the potential to replace current graft products, offering enhanced safety and superior bone fusion for patients with complex comorbidities, ultimately improving recovery outcomes and surgical success. ? As investors in Novadip, we are proud to support this transformative journey, delivering safe and easy-to-use solutions to the patients who need them most. ? ? This is the perfect timing for Novadip, as the company prepares for its $50M fundraising round!?? #funding #nonunion #SpineSurgery #FDAApproval #NVDX3 #HealthTech #ClinicalTrials

?? We are delighted to announce our VIVES portfolio company BiocSol has secured €5.2M in seed funding! ? ?? Built on a decade of research at Université catholique de Louvain, BiocSol is redefining sustainable agriculture with its next-generation microbial-based solutions. By using secondary metabolites, these eco-friendly innovations deliver enhanced stability and effectiveness, ensuring reliable protection for key crops like potatoes, grapes, and vegetables—paving the way for a more sustainable future in farming.?? ? VIVES co-led the round with Agri Investment Fund bringing in new investors, invest.bw and IMBC SPINNOVA SA?onboard ?? ? Warm congrats to Denis Payen and Simon Caulier for this incredible milestone ? Read the full press release ?? https://lnkd.in/dvHqmKMU ? #agtech #midldew #lateblight #biofungicide #cropcare #sustainability #innovation #agriculture #farming #impact #resilience #UCLouvain

?? Exciting progress in European collaboration for Space Situational Awareness (#SSA)! ?? The SPRING project, supported by the #EU #EDF programme, has brought together #SMEs across Europe, fostering collaboration to develop cutting-edge Protect & Defend capabilities for both Ground and Space-Based SSA. By leveraging the diverse expertise of small and medium-sized enterprises, the project has accelerated innovation and created novel solutions to ensure the security and sustainability of our space environment. From early-stage threat detection to real-time space object tracking, the SPRING project is empowering SMEs to play a pivotal role in strengthening Europe’s space capabilities. Together, we’re building a safer, more resilient space ecosystem for the future! ? #Space #SpaceSecurity #SSP #Innovation #EuropeanCollaboration #SMEs #SpaceSituationalAwareness #SpaceDefense #ProtectAndDefend Aldoria Nurjana Technologies Sybilla Technologies AIKO - Infinite ways to autonomy

Université Paris Cité will attend AI for Health on November 21st at STATION F! Don't miss Stéphanie Allassonniere on the main stage at 11h40 for the topic: Exploring New Foundation Models for Health Research Happy for a chat and discuss how you can collaborate with the largest health campus in Europe (Université Paris Cité) and support the ambition of the national strategy for AI in Health! ?? Emmanuel Bacry Stanislas de Montlebert Pasdeloup-Roque Samantha Stéphanie Lefebvre Ridha Bennour, HEC Executive MBA Sandra Kanani, PhD MBA Delphine Nouvian Alexis Bruhat Jean-Christophe Dantonel Nathalie Varoqueaux MD PhD Carole Oudot Philippe Durieux Dr Jean Louis Fraysse Jean-Emmanuel Bibault Fatine EL JEBBARI Lucas Fialaire Hélène Chautard David Bonnafous SOPHIE HOEHLINGER Leslie Dubrana Agnès De Leersnyder Pierre Burguière, PhD David Marques Tara DUONG Marc de Garidel Fabrice Rosenstiehl Giuseppina Caligiuri Mehdi BANAHA, PhD

We are thrilled to welcome atbtherapeutics to our expanding biotechnology portfolio! ?Congratulations to founders Bertrand Magy and Max Houry on securing a remarkable €54M Series A financing co-led by EQT Life Sciences and MRL Ventures Fund LLC (corporate venture arm of Merck & Co., Inc., Rahway, N.J., USA) with contributions from V-Bio Ventures, SFPIM, Wallonie Entreprendre, Sambrinvest and several historic investors. ??? ? With industry veteran Mark Throsby as executive chair, ATB is dedicated to pioneering First-in-Class biologics that incorporate novel cell-killing mechanisms, including enzymatic functionalities within targeted antibodies. Their proprietary ATBioFarm platform aims to deliver unique “weaponized” antibodies for oncology and immunology applications??? #biotech #innovation #antibody #oncology #immunology #SeriesA Fournier-Majoie Foundation Noshaq INVESTSUD Read more about the fundraising???

We visited de Duve Institute to celebrate their 50th Birthday ?? ?? The de Duve Institute is a world-renowned multidisciplinary biomedical research center that houses several research laboratories within the Faculty of Medicine at the Catholic University of Louvain (Université catholique de Louvain). Professor Frank Aboubakar (3rd from the left), a specialist in thoracic and lung cancer at Cliniques universitaires Saint-Luc, along with his colleague Thibaut Hirsh (2nd from the left), a postdoctoral researcher at the de Duve Institute, explained their ongoing research on the role of neutrophils. The presence of these white blood cells in patients' tumors is associated with poor prognosis. Their work aims to unravel how neutrophils impede the anti-tumor immune response, with the goal of identifying new therapeutic targets to enhance the effectiveness of cancer immunotherapy treatments. The de Duve Institute is also home to our portfolio company, iTeos Therapeutics, which leverages its expertise in tumor immunology, translational medicine, and drug discovery to develop the next generation of immunotherapies. Their approach targets the tumor microenvironment to boost the efficiency of immune cells in eradicating cancer. Our motto: making science investable for the benefit of patients ?? #research #excellence #anniversary #health #UCLouvain #Iteos #VIVES